Systemic Delivery of Calcium Channel Blockers for Hypertension through Transdermal Delivery - A Review

Abstract:

Hypertension is a significant public health challenge, responsible for a substantial proportion of deaths and disability globally. Calcium Channel Blockers (CCBs) are an essential class for the treatment of hypertension. However, most of CCBs must be taken more than once daily due to their low oral bioavailability and limited half-life, leading to non-compliance in patients. The development of delivery methods for CCBs is an ongoing effort to overcome the issues related to their delivery via their traditional forms. The administration of the drug through the skin for systemic delivery has been recognised as one of the potential routes in hypertension treatment, especially when drugs suffer from low bioavailability, undesirable side effects and short biological half-life following oral administration. The main limitation of transdermal drug delivery is the resistance barrier of skin layers to penetrant molecules. Remarkable research efforts have been made worldwide to minimise the skin barrier and to create transdermal systems of several CCBs via employing skin-enhancing potential. The persistent progress in this field is promising for development the transdermal dosage forms advance technology in the long term and being commercialised sooner rather than later. This review explores the investigations on the viability and applicability of systemic delivery of numerous CCBs through the skin.

• Periodical: Materials Science Forum (Volume 1025)
• Pages: 204-208
• DOI: https://doi.org/10.4028/www.scientific.net/MSF.1025.204
• Online since: March 2021
• Authors: Khater Ahmed Saeed AL-Japairai, Syed Mahmood*
• Keywords: Bioavailability, Calcium Channel Blockers, Hypertension, Skin, Transdermal Drug Delivery

References

[1] T. D. Giles, B. J. Materson, J. N. Cohn, and J. B. Kostis, Definition and classification of hypertension: an update,, J. Clin. Hypertens., vol. 11, no. 11, p.611–614, (2009).

DOI: 10.1111/j.1751-7176.2009.00179.x

[2] S. Jain and S. C. Joshi, Development of transdermal matrix system of captopril based on cellulose derivative,, Pharmacolgyonline, vol. 1, p.379–390, (2007).

[3] F. Gohar, S. M. Greenfield, D. G. Beevers, G. Y. H. Lip, and K. Jolly, Self-care and adherence to medication: a survey in the hypertension outpatient clinic,, BMC Complement. Altern. Med., vol. 8, no. 1, p.4, (2008).

DOI: 10.1186/1472-6882-8-4

[4] K. A. S. Al-Japairai et al., Current trends in polymer microneedle for transdermal drug delivery,, Int. J. Pharm., vol. 587, (2020).

[5] M. Azmana, S. Mahmood, A. R. Hilles, U. K. Mandal, K. A. S. Al-Japairai, and S. Raman, Transdermal drug delivery system through polymeric microneedle: A recent update,, J. Drug Deliv. Sci. Technol., vol. 60, p.101877, (2020).

DOI: 10.1016/j.jddst.2020.101877

[6] S. Mahmood, M. Taher, and U. K. Mandal, Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application,, Int. J. Nanomedicine, vol. 9, p.4331, (2014).

DOI: 10.2147/ijn.s65408

[7] M. R. Prausnitz and R. Langer, Transdermal drug delivery,, Nat. Biotechnol., vol. 26, no. 11, p.1261–1268, (2008).

DOI: 10.1038/nbt.1504

[8] M. M. R. Siddiqui, S. S. B. Mosharraf, R. S. Giasuddin, N. Islam, and S. Mirza, What is New in New Generation Calcium Channel Blocker,, Anwer Khan Mod. Med. Coll. J., vol. 10, no. 1, p.77–83, (2019).

DOI: 10.3329/akmmcj.v10i1.43666

[9] Y. Ozawa, K. Hayashi, and H. Kobori, New generation calcium channel blockers in hypertensive treatment,, Curr. Hypertens. Rev., vol. 2, no. 2, p.103–111, (2006).

DOI: 10.2174/157340206776877370

[10] T. F. Lüscher and F. Cosentino, The classification of calcium antagonists and their selection in the treatment of hypertension,, Drugs, vol. 55, no. 4, p.509–517, (1998).

DOI: 10.2165/00003495-199855040-00003

[11] R. Jain, M. Aqil, A. Ahad, A. Ali, and R. K. Khar, Basil oil is a promising skin penetration enhancer for transdermal delivery of labetolol hydrochloride,, Drug Dev. Ind. Pharm., vol. 34, no. 4, p.384–389, (2008).

DOI: 10.1080/03639040701657958

[12] S. Bindhani, U. Mohapatra, S. Mohapatra, and R. K. Kar, Enhancement of Solubility and Dissolution Rate of Poorly Soluble Drug Nifedipine by Solid Sedds,, Int. J. Drug Deliv. Technol., vol. 10, no. 1, p.9–15, (2020).

DOI: 10.25258/ijddt.10.1.3

[13] G. Chandra, K. S., & Ramesh, The fourth-generation Calcium channel blocker: cilnidipine,, Indian Heart J., vol. 65, no. 6, p.691–695, (2013).

DOI: 10.1016/j.ihj.2013.11.001

[14] S. Güngör and Y. Özsoy, Systemic delivery of antihypertensive drugs via skin,, Ther. Deliv., vol. 3, no. 9, p.1101–1116, (2012).

DOI: 10.4155/tde.12.87

[15] R. Muzzalupo and L. Tavano, Niosomal drug delivery for transdermal targeting: recent advances,, Res. reports transdermal drug Deliv., vol. 4, p.23, (2015).

DOI: 10.2147/rrtd.s64773

[16] V. R. Yasam et al., A novel vesicular transdermal delivery of nifedipine–preparation, characterization and in vitro/in-vivo evaluation,, Drug Deliv., vol. 23, no. 2, p.619–630, (2016).

DOI: 10.3109/10717544.2014.931484

[17] B. Morakul and V. B. Junyaprasert, Proniosomes: An effective carrier for dermal and transdermal delivery,, (2019).

[18] M. Yusuf, V. Sharma, and K. Pathak, Nanovesicles for transdermal delivery of felodipine: Development, characterization, and pharmacokinetics,, Int. J. Pharm. Investig., vol. 4, no. 3, p.119, (2014).

DOI: 10.4103/2230-973x.138342

[19] K. D. Dhondge, D. M. Patil, A. A. Patak, and D. S. Pachpute, Formulation development and characterization of transdermal film of nisoldipine,, Int J Pharm Sci, vol. 5, p.313–323, (2014).

[20] M. Yasir, M. Asif, A. Kumar, and A. Aggarval, Biopharmaceutical classification system: An account,, Int. J. PharmTech Res., vol. 2, no. 3, p.1681–1690, (2010).

[21] G. M. El Maghraby, A. A. Ahmed, and M. A. Osman, Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery,, Saudi Pharm. J., vol. 23, no. 1, p.67–74, (2015).

DOI: 10.1016/j.jsps.2014.05.001

[22] Y. Luo, L. Ren, M. Jiang, and Y. Chu, Anti-hypertensive efficacy of amlodipine dosing during morning versus evening: A meta-analysis,, Rev. Cardiovasc. Med., vol. 20, no. 2, p.91–98, (2019).

DOI: 10.31083/j.rcm.2019.02.31814

[23] H. Kapoor, M. Aqil, S. S. Imam, Y. Sultana, and A. Ali, Formulation of amlodipine nano lipid carrier: formulation design, physicochemical and transdermal absorption investigation,, J. Drug Deliv. Sci. Technol., vol. 49, p.209–218, (2019).

DOI: 10.1016/j.jddst.2018.11.004

[24] M. M. Shete, Cilnidipine: Next generation calcium channel blocker,, J Assoc Physicians India, vol. 64, no. 4, p.95–99, (2016).

[25] R. Diwan, P. R. Ravi, N. S. Pathare, and V. Aggarwal, Pharmacodynamic, pharmacokinetic and physical characterization of cilnidipine loaded solid lipid nanoparticles for oral delivery optimized using the principles of Design of Experiments,, Colloids Surfaces B Biointerfaces, p.111073, (2020).

DOI: 10.1016/j.colsurfb.2020.111073

[26] K. Khatoon, M. Rizwanullah, S. Amin, S. R. Mir, and S. Akhter, Cilnidipine loaded transfersomes for transdermal application: Formulation optimization, in-vitro and in-vivo study,, J. Drug Deliv. Sci. Technol., vol. 54, p.101303, (2019).

DOI: 10.1016/j.jddst.2019.101303

[27] N. Jain, A. Argal, and G. Gautam, Elastic liposomes mediated transdermal delivery of verapamil hydrochloride,, J. Drug Deliv. Ther., vol. 8, no. 6, p.16–21, (2018).

DOI: 10.22270/jddt.v8i6.2073

[28] R. Parhi and P. Suresh, Transdermal delivery of Diltiazem HCl from matrix film: Effect of penetration enhancers and study of antihypertensive activity in rabbit model,, J. Adv. Res., vol. 7, no. 3, p.539–550, (2016).

DOI: 10.1016/j.jare.2015.09.001